Emerging roles for endothelial mineralocorticoid receptor in disease pathogenesis: potential new indications for mineralocorticoid receptor antagonism. [PDF]
Curr Opin PhysiolAn W, Jaffe IZ.
europepmc +1 more source
Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial. [PDF]
BMJ Neurol OpenWard K +29 more
europepmc +1 more source
Korean Red Ginseng attenuates glucocorticoid-induced skin barrier dysfunction via mineralocorticoid receptor modulation. [PDF]
J Ginseng ResLee JW +6 more
europepmc +1 more source
Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials. [PDF]
JACC AdvKido K, Hashiguchi M, Guglin M.
europepmc +1 more source
Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation. [PDF]
Nat CommunWang CA +7 more
europepmc +1 more source
Finerenone in mildly reduced or preserved ejection fraction and chronic kidney disease: a narrative review. [PDF]
Egypt Heart JFaheem MSB +4 more
europepmc +1 more source
Cardiovascular Benefits of Spironolactone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from a Win Ratio Analysis of the TOPCAT Trial. [PDF]
Card Fail RevNguyen DV, Nguyen HTT.
europepmc +1 more source
Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption. [PDF]
PLoS MedLaffin LJ, Nissen SE.
europepmc +1 more source
Integrating Structural, Biochemical, and Cellular Perspectives on the TFIIH Helicases XPB and XPD. [PDF]
BiomoleculesBravo M, Fan L.
europepmc +1 more source